Eakley Rachel, Lyndon Audrey
New York University, Rory Meyers College of Nursing, New York, New York.
J Midwifery Womens Health. 2024 Nov-Dec;69(6):847-862. doi: 10.1111/jmwh.13679. Epub 2024 Jul 25.
Symptoms of untreated depression and anxiety during pregnancy are associated with serious adverse effects for the pregnant person, birth outcomes, and child development. However, pregnant persons are less likely to be screened and treated compared with nonpregnant people. In this systematic review, we aimed to explore individual, provider, and systems factors that impact screening, identification, and treatment patterns for depression and anxiety during pregnancy.
Studies were eligible for inclusion if they were conducted within the United States and published in English between January 2012 and January 2023. Each study included analysis that compared rates of screening, identification, or treatment engagement and explicitly discussed disparities or health equity in marginalized groups. Fifteen articles met full inclusion criteria.
Results demonstrated variation in the screening, identification, and treatment of depression and anxiety during pregnancy among diverse groups of patients. Screening rates ranged from 51.3% in Puerto Rico to 90.7% in Alaska. Among specific clinical populations, rates were as low as 2.0%. Fewer than half of patients were referred to treatment when indicated by screening or diagnoses. Patient characteristics such as age, race, ethnicity, socioeconomic and health factors, mental health history, and obesity were associated with variation in the rates of screening, diagnoses, or treatment engagement. Language factors were the most common factor associated with lower rates of screening and treatment access.
Results suggest that many pregnant people are being overlooked and lack appropriate referrals or resources to access treatment. Results are consistent with previous findings that role confusion and lack of time, provider training, and interest contribute to low rates of screening and treatment. Future research must focus on system level factors to address perceived barriers to screening and treating depression and anxiety during pregnancy in a systematic and equitable way.
孕期未经治疗的抑郁和焦虑症状会给孕妇、分娩结局和儿童发育带来严重不良影响。然而,与非孕妇相比,孕妇接受筛查和治疗的可能性较小。在这项系统评价中,我们旨在探讨影响孕期抑郁和焦虑筛查、识别及治疗模式的个体、医疗服务提供者和系统因素。
如果研究是在美国境内开展,并于2012年1月至2023年1月期间以英文发表,则 eligible for inclusion。每项研究都包括对筛查、识别或治疗参与率进行比较的分析,并明确讨论了边缘化群体中的差异或健康公平问题。15篇文章符合完全纳入标准。
结果表明,不同患者群体在孕期抑郁和焦虑的筛查、识别及治疗方面存在差异。筛查率从波多黎各的51.3%到阿拉斯加的90.7%不等。在特定临床人群中,这一比例低至2.0%。当筛查或诊断表明需要治疗时,只有不到一半的患者被转诊接受治疗。年龄、种族、民族、社会经济和健康因素、心理健康史以及肥胖等患者特征与筛查、诊断或治疗参与率的差异有关。语言因素是与较低筛查率和治疗可及性相关的最常见因素。
结果表明,许多孕妇被忽视,缺乏适当的转诊或资源来获得治疗。这些结果与之前的研究结果一致,即角色混乱、时间不足、医疗服务提供者培训不足以及缺乏兴趣导致筛查和治疗率较低。未来的研究必须关注系统层面的因素,以系统且公平的方式解决孕期抑郁和焦虑筛查及治疗中存在的明显障碍。